Sutcliffe Research Group
Sutcliffe Research Group

MANchester DRug Analysis & Knowledge Exchange (MANDRAKE)

MANchester DRug Analysis and Knowledge Exchange (or MANDRAKE) - is a licenced scientific resource, based at Manchester Metropolitan University, working in partnership with key stakeholders to facilitate rapid, robust and cost-effective chemical analysis for both harm-reduction and intelligence sharing.

MANDRAKE is England's FIRST publically-funded permanent city-centre based testing and harm reduction facility, operating since 2016, supporting openscience and agencies working towards safeguarding the public. Click HERE for images of the team in action.

MANDRAKE undertaking harm reduction activities at Manchester Pride (2017)

The partnership which operates two permenant state-of-the-art, fully equipped laboratories, is working on a number of intelligence sharing projects to safeguard communities through drug awareness & harm-reduction – including the chemical analysis of Spice used within the city centre homeless community, which has led to the publication of a GM-wide Spice Warning Information Leaflet (March 2017) and Professional Briefing (July 2017) for health, drug and homeless support service providers [see pdf links below].


Since 2016, MANDRAKE has signed agreements with a number of UK-based charities, law enforcement agencies and industrial partners to proactively work with them to tackle the issues associated with emerging threats including synthetic opiates (fentanyl and its analogues) and MDPHP (aka. Monkey Dust). 


In addition MANDRAKE is research-active and has published its findings in numerous internationally-recognised peer-reviewed journals (MANDRAKE Research).

MANDRAKE Testing Facilities, Manchester Metropolitan University (2017)

For further information on the work of the MANDRAKE partnership click HERE.  The contact details for the partnership are below:


Dr Oliver Sutcliffe

Director of MANDRAKE


Spice Warning Information Leaflet
Adobe Acrobat document [553.4 KB]
Spice / Synthetic Cannabinoid (SCRA) Briefing for Professionals
Adobe Acrobat document [1.6 MB]
Print Print | Sitemap
© Oliver Sutcliffe